|
1
|
Leone RD and Powell JD: Metabolism of
immune cells in cancer. Nat Rev Cancer. 20:516–531. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Andrews LP, Yano H and Vignali DAA:
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4:
Breakthroughs or backups. Nat Immunol. 20:1425–1434.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Doroshow DB, Bhalla S, Beasley MB, Sholl
LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS and Hirsch FR:
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Nat Rev Clin Oncol. 18:345–362. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Islam MK and Stanslas J: Peptide-based and
small molecule PD-1 and PD-L1 pharmacological modulators in the
treatment of cancer. Pharmacol Ther. 227(107870)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US food
and drug administration (FDA) approvals of immune checkpoint
inhibitors. J Immunother Cancer Oct. 7(278)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sosa A, Cadena EL, Olive CS, Karachaliou N
and Rosell R: Clinical assessment of immune-related adverse events.
Ther Adv Med Oncol. 10(1758835918764628)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Coniac S and Stoian M: Updates in
endocrine immune-related adverse events in oncology immunotherapy.
Acta Endocrinol (Buchar). 17:286–289. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang
X, Zhang X, Xu J, Fei K, Zhang Z, et al: Treatment-related adverse
events of PD-1 and PD-L1 inhibitor-based combination therapies in
clinical trials: A systematic review and meta-analysis. Lancet
Oncol. 22:1265–1274. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wright JJ, Powers AC and Johnson DB:
Endocrine toxicities of immune checkpoint inhibitors. Nat Rev
Endocrinol. 17:389–399. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cukier P, Santini FC, Scaranti M and Hoff
AO: Endocrine side effects of cancer immunotherapy. Endocr Relat
Cancer. 24:T331–T347. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ferrari SM, Fallahi P, Galetta F, Citi E,
Benvenga S and Antonelli A: Thyroid disorders induced by checkpoint
inhibitors. Rev Endocr Metab Disord. 19:325–333. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhou X, Wu L, Chen Y, Xiao H, Huang X, Li
Y, Xiao H and Cao X: Forty-eight weeks of statin therapy for type 2
diabetes mellitus patients with lower extremity atherosclerotic
disease: Comparison of the effects of pitavastatin and atorvastatin
on lower femoral total plaque areas. J Diabetes Investig.
12:1278–1286. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fang C, Liu T, Liang W, Feng S, Su Z, Tang
H, Huang H and Chen Z: Clinical pharmacist participation in
selecting and dosing targeted drugs for a patient with ALK-positive
non-small cell lung cancer: A case report. Ann Transl Med.
9(1488)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: KEYNOTE-001 investigators. Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med. 372:2018–2028.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Presotto EM, Rastrelli G, Desideri I,
Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo
F, Bruggia M, et al: Endocrine toxicity in cancer patients treated
with nivolumab or pembrolizumab: Results of a large multicentre
study. J Endocrinol Invest. 43:337–345. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Król A, Gawlik T and Jarząb B: Endocrine
complications of cancer immunotherapy. Endokrynol Pol. 69:722–733.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ,
Li SW, Liu N and Yan CX: Immune-related adverse events associated
with anti-PD-1/PD-L1 treatment for malignancies: A meta-analysis.
Front Pharmacol. 8(730)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J and Jordan K: ESMO guidelines committee.
Management of toxicities from immunotherapy: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
28:iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nogueira E, Newsom-Davis T and Morganstein
DL: Immunotherapy-induced endocrinopathies: Assessment, management
and monitoring. Ther Adv Endocrinol Metab.
10(2042018819896182)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xie J, Zhang Z, Zhang S, Lv Y, Mao Y, Liu
R and Tian Y: Odds ratio of programmed cell death-1 or ligand 1
inhibitor-related endocrine dysfunction in patients with lung
cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 98(e18310)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mantia CM and Buchbinder EI: Immunotherapy
toxicity. Hematol Oncol Clin North Am. 33:275–290. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Marchand L, Thivolet A, Dalle S, Chikh K,
Reffet S, Vouillarmet J, Fabien N, Cugnet-Anceau C and Thivolet C:
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: Description
of pancreatic endocrine and exocrine phenotype. Acta Diabetol.
56:441–448. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tucker CG, Dwyer AJ, Fife BT and Martinov
T: The role of programmed death-1 in type 1 diabetes. Curr Diab
Rep. 21(20)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pollack R, Kagan M, Dresner-Pollak R and
Neuman T: PD-L1 expression in normal endocrine tissues is not
increased despite high incidence of PD-1 inhibitor-associated
endocrinopathies. Endocr Pract. 27:34–37. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Álvarez-Sierra D, Marín-Sánchez A,
Ruiz-Blázquez P, de Jesús Gil C, Iglesias-Felip C, González Ó,
Casteras A, Costa RF, Nuciforo P, Colobran R and Pujol-Borrell R:
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid
disease: Insights into pathogenesis and clues to immunotherapy
associated thyroid autoimmunity. J Autoimmun.
103(102285)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Okada N, Iwama S, Okuji T, Kobayashi T,
Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, et al:
Anti-thyroid antibodies and thyroid echo pattern at baseline as
risk factors for thyroid dysfunction induced by anti-programmed
cell death-1 antibodies: A prospective study. Br J Cancer.
122:771–777. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Toi Y, Sugawara S, Sugisaka J, Ono H,
Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, et al:
Profiling preexisting antibodies in patients treated with anti-PD-1
therapy for advanced non-small cell lung cancer. JAMA Oncol.
5:376–383. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Muir CA, Wood CCG, Clifton-Bligh RJ, Long
GV, Scolyer RA, Carlino MS, Menzies AM and Tsang VHM: Association
of anti-thyroid antibodies in checkpoint inhibitor associated
thyroid immune related adverse events. J Clin Endocrinol Metab.
1:e1843–e1849. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tan MH, Iyengar R, Mizokami-Stout K, Yentz
S, MacEachern MP, Shen LY, Redman B and Gianchandani R: Spectrum of
immune checkpoint inhibitors-induced endocrinopathies in cancer
patients: A scoping review of case reports. Clin Diabetes
Endocrinol. 5(1)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Angell TE, Min L, Wieczorek TJ and Hodi
FS: Unique cytologic features of thyroiditis caused by immune
checkpoint inhibitor therapy for malignant melanoma. Genes Dis.
5:46–48. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ferrari SM, Fallahi P, Elia G, Ragusa F,
Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G
and Antonelli A: Autoimmune endocrine dysfunctions associated with
cancer immunotherapies. Int J Mol Sci. 20(2560)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ma C, Hodi FS, Giobbie-Hurder A, Wang X,
Zhou J, Zhang A, Zhou Y, Mao F, Angell TE, Andrews CP, et al: The
impact of high-dose glucocorticoids on the outcome of
immune-checkpoint inhibitor-related thyroid disorders. Cancer
Immunol Res. 7:1214–1220. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nicolè S, Lanzafame M, Cazzadori A,
Vincenzi M, Mangani F, Colato C, El Dalati G, Brazzarola P and
Concia E: Successful antifungal combination therapy and surgical
approach for aspergillus fumigatus suppurative thyroiditis
associated with thyrotoxicosis and review of published reports.
Mycopathologia. 182:839–845. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Byun DJ, Braunstein R, Flynn J, Zheng J,
Lefkowitz RA, Kanbour S and Girotra M: Immune checkpoint
inhibitor-associated diabetes: A single-institution experience.
Diabetes Care. 43:3106–3109. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Stamatouli AM, Quandt Z, Perdigoto AL,
Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A,
Rushakoff R, et al: Collateral damage: Insulin- dependent diabetes
induced with checkpoint inhibitors. Diabetes. 67:1471–1480.
2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Quandt Z, Young A and Anderson M: Immune
checkpoint inhibitor diabetes mellitus: A novel form of autoimmune
diabetes. Clin Exp Immunol. 200:131–140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kyriacou A, Melson E, Chen W and
Kempegowda P: Is immune checkpoint inhibitor-associated diabetes
the same as fulminant type 1 diabetes mellitus? Clin Med (Lond).
20:417–423. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Martin-Liberal J, Furness AJ, Joshi K,
Peggs KS, Quezada SA and Larkin J: Anti-programmed cell death-1
therapy and insulin-dependent diabetes: A case report. Cancer
Immunol Immunother. 64:765–767. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Li S, Zhang Y, Sun Z, Hu J and Fang C:
Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese
patient: A case report. Medicine (Baltimore). 67:1471–1480.
2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Godwin JL, Jaggi S, Sirisena I, Sharda P,
Rao AD, Mehra R and Veloski C: Nivolumab-induced autoimmune
diabetes mellitus presenting as diabetic ketoacidosis in a patient
with metastatic lung cancer. J Immunother Cancer.
5(40)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lee S, Morgan A, Shah S and Ebeling PR:
Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy.
Endocrinol Diabetes Metab Case Rep. 2018:18–0021. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lupi I, Brancatella A, Cosottini M, Viola
N, Lanzolla G, Sgrò D, Dalmazi GD, Latrofa F, Caturegli P and
Marcocci C: Clinical heterogeneity of hypophysitis secondary to
PD-1/PD-L1 blockade: Insights from four cases. Endocrinol Diabetes
Metab Case Rep. 2019:19–0102. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sothornwit J, Phunmanee A and
Pongchaiyakul C: Atezolizumab-induced autoimmune diabetes in a
patient with metastatic lung cancer. Front Endocrinol (Lausanne).
10(352)2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Patel S, Chin V and Greenfield JR:
Durvalumab-induced diabetic ketoacidosis followed by
hypothyroidism. Endocrinol Diabetes Metab Case Rep. 2019:19–0098.
2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Skorpen PK and Margull J: Diabetic
ketoacidosis following immunotherapy for lung cancer. Tidsskr Nor
Laegeforen. 139(10.4045/tidsskr.18.0597)2019.PubMed/NCBI View Article : Google Scholar : (In English,
Norwegian).
|
|
47
|
Leonardi GC, Oxnard GR, Haas A, Lang JP,
Williams JS and Awad MM: Diabetic ketoacidosis as an immune-related
adverse event from pembrolizumab in non-small cell lung cancer. J
Immunother. 40:249–251. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kusuki K, Suzuki S and Mizuno Y:
Pembrolizumab-induced fulminant type 1 diabetes with C-peptide
persistence at first referral. Endocrinol Diabetes Metab Case Rep:
Apr 29, 2020 (Epub ahead of print).
|
|
49
|
Ishi A, Tanaka I, Iwama S, Sakakibara T,
Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H and
Hashimoto N: Efficacies of programmed cell death 1 ligand 1
blockade in non-small cell lung cancer patients with acquired
resistance to prior programmed cell death 1 inhibitor and
development of diabetic ketoacidosis caused by two different
etiologies: A retrospective case series. Endocr J. 68:613–620.
2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Alrifai T, Ali FS, Saleem S, Ruiz DCM,
Rifai D, Younas S and Qureshi F: Immune checkpoint inhibitor
induced diabetes mellitus treated with insulin and metformin:
Evolution of diabetes management in the era of immunotherapy. Case
Rep Oncol Med. 2019(8781347)2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kedzior SK, Jacknin G, Hudler A, Mueller
SW and Kiser TH: A severe case of diabetic ketoacidosis and
new-onset type 1 diabetes mellitus associated with anti-glutamic
acid decarboxylase antibodies following immunotherapy with
pembrolizumab. Am J Case Rep. 22(e931702)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Barroso-Sousa R, Barry WT, Garrido-Castro
AC, Hodi FS, Min L, Krop IE and Tolaney SM: Incidence of endocrine
dysfunction following the use of different immune checkpoint
inhibitor regimens: A systematic review and meta-analysis. JAMA
Oncol. 4:173–182. 2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Tahir SA, Gao J, Miura Y, Blando J,
Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, et al:
Autoimmune antibodies correlate with immune checkpoint
therapy-induced toxicities. Proc Natl Acad Sci USA.
116:22246–22251. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Faje AT, Sullivan R, Lawrence D, Tritos
NA, Fadden R, Klibanski A and Nachtigall L: Ipilimumab-induced
hypophysitis: A detailed longitudinal analysis in a large cohort of
patients with metastatic melanoma. J Clin Endocrinol Metab.
99:4078–4085. 2014.PubMed/NCBI View Article : Google Scholar
|
